Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of 4-Quinazolinone-Containing Phenylalanine Derivatives as Potent, Resistant-Tolerant HIV Capsid Inhibitors.

MedComm·2026
Same author

Prion Protein-Derived Cell-Penetrating Peptide Inhibits Type II Diabetes-Associated Islet Amyloid Polypeptide Aggregation and Cytotoxicity.

Biochemistry·2026
Same author

Discovery of novel diarylpyrimidine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors: Design, synthesis and biological activity evaluation.

Bioorganic chemistry·2026
Same author

O-glycosylated peptides curtail the aggregation and toxicity of human islet amyloid polypeptide.

Communications biology·2025
Same author

A Polyproline Type II Peptidomimetic Disrupts a Grb2 SH3C Domain Protein-Protein Interaction Implicated in Breast Cancer.

Chembiochem : a European journal of chemical biology·2025
Same author

Anti-HIV diterpenoids from Daphne pseudomezereum.

Phytochemistry·2024

Related Experiment Video

Updated: May 23, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Blocking HIV-1 entry by a gp120 surface binding inhibitor.

Lun K Tsou1, Chin-Ho Chen, Ginger E Dutschman

  • 1Department of Chemistry, Yale University, New Haven, CT 06520, United States.

Bioorganic & Medicinal Chemistry Letters
|April 11, 2012
PubMed
Summary

A novel proteomimetic compound effectively blocks HIV-1 entry by targeting the gp120 protein surface. This new viral entry inhibitor shows potent activity against various HIV-1 strains, including drug-resistant ones.

More Related Videos

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
07:22

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

Published on: August 14, 2018

Related Experiment Videos

Last Updated: May 23, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
07:22

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

Published on: August 14, 2018

Area of Science:

  • Virology
  • Immunology
  • Drug Discovery

Background:

  • Human Immunodeficiency Virus type 1 (HIV-1) entry into host cells is a critical step in viral replication.
  • The viral envelope glycoprotein gp120 plays a crucial role in mediating HIV-1 attachment and entry.
  • Developing novel inhibitors targeting viral entry remains a priority for HIV/AIDS therapeutics.

Purpose of the Study:

  • To elucidate the mechanism of action of a novel proteomimetic compound designed to inhibit HIV-1 entry.
  • To characterize the compound's interaction with the gp120 protein and its effect on viral entry pathways.
  • To evaluate the compound's anti-HIV-1 activity against diverse viral strains.

Main Methods:

  • One-cycle time-of-addition assays were employed to study the stage of viral entry inhibited by the compound.
  • Antibody competition binding studies were conducted to investigate the compound's interaction site on gp120.
  • Antiviral activity was assessed against pseudotyped viruses derived from primary HIV-1 isolates and drug-resistant strains.

Main Results:

  • The proteomimetic compound binds to the exterior surface of gp120, a key viral protein.
  • The compound was found to block HIV-1 entry by modulating critical protein-protein interactions involving gp120.
  • The compound demonstrated potent anti-HIV-1 replication activity against multiple pseudotyped viruses, including those resistant to existing drugs.

Conclusions:

  • The proteomimetic compound represents a new class of HIV-1 viral entry inhibitors.
  • Its mechanism of action involves targeting protein surface recognition on gp120, similar to antibody binding.
  • This compound offers a promising new strategy for combating HIV-1 infection, including against resistant strains.